Søgning på udtrykket 'cvid' giver 15 resultater
Dokumenter [5]
Sider [1]
Kalender [1]
Nyt fra tidsskrifterne [8]
Dokumenter [5]
Denne vejledning er tiltænkt behandling af CVID hos voksne patienter. Der er ikke foretaget en gradering af evidensniveau, da der ikke foreligger solid evidens for flere dele af feltet.
Den aktuelle udgave er opdateret med anvendelse af PCV20.
Denne vejledning er tiltænkt diagnostik og kontrol af CVID hos voksne patienter. Der er ikke foretaget en gradering af evidensniveau, da der ikke foreligger solid evidens for flere dele af feltet.
Den aktulle udgave er opdateret med PCV20.
Udarbejdet af Hanne V. Marquart, Carsten Heilmann, Terese Katzenstein, Carsten Schade Larsen, Klaus Müller, Thomas Hoffman, Helene Ingels, Lars P. Ryder, Thyge Lynghøj Nielsen, Niels Fisker, Jens Erik Veirum
Denne vejledning er tiltænkt behandling af CVID hos voksne patienter. Der er ikke foretaget en gradering af evidensniveau, da der ikke foreligger solid evidens for flere dele af feltet.
Denne vejledning er tiltænkt diagnostik og kontrol af CVID hos voksne patienter. Der er ikke foretaget en gradering af evidensniveau, da der ikke foreligger solid evidens for flere dele af feltet.
Sider [1]
….
COVID-19 følger (2021),
Primær immundefekt:
Mette Stærkind, Carsten Schade Larsen; Susanna Deutch, Olav Ditlevsen Larsen, Line Dahlerup Rasmussen, Ann-Brit Eg Hansen, Terese Katzenstein, Birgitte Lindegaard, Lene Surland Knudsen
CVID behandling,
CVID udredning og opfølgning,
Rationel antibiotikaanvendelse:
Trine Langfeldt Hagen (tovholder), Shakil Shakar, Susanna Deutch, Kristina Öbrinck, Mathias Hertz, Isik Johansen, Christian Kraef, Jon Gitz Holler, Mette Vang…
Kalender [1]
19. maj 2022, Online og Aarhus Universitetshospital
Nyt fra tidsskrifterne [8]
Clinical & Experimental Immunology
27.12.2022
AbstractCommon variable immunodeficiency (CVID) is a “late-onset” primary immunodeficiency characterized by variable manifestations and genetic heterogeneity. A monogenic cause of CVID has been reported in 10% of patients. In this study, we identified two novel pathogenic variants implicated in monogenic CVID by whole exome sequencing (WES) analysis: a heterozygous nuclear factor κB subunit 1 (NFKB1) p.G686fs mutation and a homozygous inducible T-cell co-stimulator (ICOS) p.L96Sfs mutation. The predict…
Clinical & Experimental Immunology
25.02.2021
Clinical & Experimental Immunology, EarlyView.
Clinical & Experimental Immunology
3.02.2024
Summary . Selective IgA deficiency (sIgAD) and Common Variable Immunodeficiency (CVID) and Transient Hypogammaglobulinemia of Infancy (THI) are the most frequent forms of primary antibody deficiencies. Difficulties in initial diagnosis, especially in the early childhood, the familiar occurrence of these diseases, as well as the possibility of progression to each other suggest common cellular and molecular patomechanism and a similar genetic background. In this review, we discuss both similarities and differ…
Clinical & Experimental Immunology
27.12.2022
AbstractCommon variable immunodeficiency (CVID) is a “late-onset” primary immunodeficiency characterized by variable manifestations and genetic heterogeneity. A monogenic cause of CVID has been reported in 10% of patients. In this study, we identified two novel pathogenic variants implicated in monogenic CVID by whole exome sequencing (WES) analysis: a heterozygous nuclear factor κB subunit 1 (NFKB1) p.G686fs mutation and a homozygous inducible T-cell co-stimulator (ICOS) p.L96Sfs mutation. The predict…
Current Opinion in Infectious Diseases
1.12.2021
…munodeficiency (CVID). High rates of CMV end-organ disease, mortality, development of CMV resistance and prolonged antiviral use have been observed in individuals with CVID. Summary We recommend that clinicians tailor their approach to the individual based on their underlying immune deficit and maintain a high index of suspicion and low threshold for treatment. More research is required to improve stratification of CMV risk in PID, develop new diagnostic tools and manage end-organ disease in this cohort.
Clinical Microbiology and Infection
10.11.2021
A 22-year-old man with common variable immunodeficiency (CVID) complicated with granulomatous–lymphocytic interstitial lung disease (GLILD) previously treated with azathioprine and a 4-weekly course of rituximab 3 years before who was receiving subcutaneous (SC) immunoglobulin replacement therapy (IRT) was diagnosed of COVID-19 by SARS-CoV-2 reverse-transcriptase-polymerase-chain-reaction (RT-PCR) of a nasopharyngeal swab specimen after a 4-day history of fever. He quarantined at home but was later admit…
BMC Infectious Diseases
23.09.2021
…viral mutations conferring antiviral drug resistance. Case presentation Here we reported the case of an HCMV seronegative patient with common variable immunodeficiency (CVID), multiple hepatic adenomatosis, hepatopulmonary syndrome and portal hypertension who received a liver transplant from an HCMV seropositive donor. The patient was treated with Valganciclovir (vGCV) and then IV Ganciclovir (GCV) at 5 week post-transpl…
Clinical Infectious Diseases
27.05.2020
…mplification. The AQSA resistance phenotype (≥45% parasite survival) was expressed in 36.5% (23/63) of isolates and was significantly associated with treatment failure (P = .0020). Pfmdr1 mutant haplotypes were N86/184F/D1246, and Pfcrt was CVIET or CVIDT at positions 72–76. Additional Pfcrt mutations were not associated with amodiaquine resistance, but the G353V mutant allele was associated with ACPR compared to Pfmdr1 haplotypes harboring F1068L or S784L/R945P mutations (P = .030 and P = .…